Gupta PB et al., 2009-08-21: The 2009 MIT/Harvard screen that produced the '>100-fold versus paclitaxel' figure – for salinomycin, a different compound, not ivermectin.
One compound, salinomycin, reduces the proportion of CSCs by >100-fold relative to paclitaxel, a commonly used breast cancer chemotherapeutic drug.
Gupta PB et al., 2009-08-21: The 2009 MIT/Harvard screen that produced the '>100-fold versus paclitaxel' figure – for salinomycin, a different compound, not ivermectin. C4 source-tracing. Study type: high-throughput chemical screen on human breast cancer cell lines plus mouse mammary tumour treatment. Country: USA (MIT, Broad Institute, Whitehead Institute, Tufts). N: cell lines and mice. Dose: not stated in the abstract captured. Funder/conflicts: not captured in the PubMed record. This is the origin of the '>100-fold' number the NaturalNews article attaches to ivermectin. Salinomycin and ivermectin are different compounds; the ivermectin paper (IVA-17) cites salinomycin only as the structural query for its similarity search.
